Ironwood Begins to Rebolster its Pipeline with Cour’s Rare Disease Drug
By Lucy Haggerty
Pharma Deals Review: Vol 2021 Issue 11 (Table of Contents)
Published: 12 Nov-2021
DOI: 10.3833/pdr.v2021.i11.2645 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In an attempt to rebuild its pipeline, Ironwood Pharmaceuticals has agreed to collaborate with Cour Pharmaceuticals to develop and commercialise the latter’s investigational candidate, CNP-104, in the US...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS